
## PaweÅ, RubiÅ>

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5735889/publications.pdf Version: 2024-02-01



<u> Ρλιμέ</u> Αμβιάς

#	Article	IF	CITATIONS
1	To what extent does prior antimicrobial therapy affect the diagnostic performance of radiolabeled leukocyte scintigraphy in infective endocarditis?. Journal of Nuclear Cardiology, 2023, 30, 343-353.	2.1	5
2	Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis. Cardiology Journal, 2022, 29, 985-993.	1.2	5
3	Clinical Utility and Validation of the Krakow DCM Risk Score—A Prognostic Model Dedicated to Dilated Cardiomyopathy. Journal of Personalized Medicine, 2022, 12, 236.	2.5	2
4	Mitral regurgitation severity dynamic during acute decompensated heart failure treatment. International Journal of Cardiovascular Imaging, 2022, 38, 1113-1119.	1.5	1
5	An expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure: Heart failure guidelines from a national perspective. Kardiologia Polska, 2022, 80, 239-246.	0.6	1
6	The Relationship between Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis and Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. Journal of Personalized Medicine, 2022, 12, 294.	2.5	1
7	Improved survival of left ventricular assist device carriers in <scp>Europe</scp> according to implantation eras: results from the <scp>PCHFâ€VAD</scp> registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	7.1	10
8	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	3.1	23
9	Sacubitril/valsartan for heart failure with reduced ejection fraction: a first real-life observational study in Poland Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland. Advances in Clinical and Experimental Medicine, 2021, 30, 67-75.	1.4	2
10	D-dimer levels predict COVID-19 severity and mortality. Authors' reply. Kardiologia Polska, 2021, 79, 218-219.	0.6	0
11	Mortality risk assessment in dilated cardiomyopathy: the Krakow DCM Risk Score. Kardiologia Polska, 2021, 79, 215-216.	0.6	3
12	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiologia Polska, 2021, 79, 363-370.	0.6	4
13	Relationships between circulating galectin-3, extracellular matrix fibrosis and outcomes in dilated cardiomyopathy. Advances in Clinical and Experimental Medicine, 2021, 30, 245-253.	1.4	6
14	Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis in Dilated Cardiomyopathy. Cells, 2021, 10, 1295.	4.1	4
15	Beyond the classic risk factors in atherosclerosis – the promise of metabolomics and other -omics in life-style acquired cardiovascular diseases. International Journal of Cardiology, 2021, 339, 167-169.	1.7	1
16	The Diagnostic Value of 99mTc-HMPAO-Labelled White Blood Cell Scintigraphy and 18F-FDG PET/CT in Cardiac Device-Related Infective Endocarditis—A Systematic Review. Journal of Personalized Medicine, 2021, 11, 1016.	2.5	10
17	Extracellular volume is an independent predictor of arrhythmic burden in dilated cardiomyopathy. Scientific Reports, 2021, 11, 24000.	3.3	7
18	The role of 99mTc-HMPAO-labelled white blood cell scintigraphy in the diagnosis of cardiac device-related infective endocarditis. European Heart Journal Cardiovascular Imaging, 2020, 21, 1022-1030.	1.2	17

PaweÅ, RubiÅ›

#	Article	IF	CITATIONS
19	Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy. Thrombosis and Haemostasis, 2020, 120, 181-183.	3.4	3
20	Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathyâ€ŧailored prognostic model. ESC Heart Failure, 2020, 7, 2455-2467.	3.1	17
21	Relationships between Pulmonary Hypertension Risk, Clinical Profiles, and Outcomes in Dilated Cardiomyopathy. Journal of Clinical Medicine, 2020, 9, 1660.	2.4	7
22	The Prognostic Value of 99mTc-HMPAO-Labeled Leucocyte SPECT/CT in CardiacÂDevice-Related Infective Endocarditis. JACC: Cardiovascular Imaging, 2020, 13, 1739-1751.	5.3	13
23	Relations between circulating and myocardial fibrosis-linked microRNAs with left ventricular reverse remodeling in dilated cardiomyopathy. Advances in Clinical and Experimental Medicine, 2020, 29, 285-293.	1.4	10
24	The burden of atrial fibrillation and its prognostic value in patients with dilated cardiomyopathy. Kardiologia Polska, 2020, 78, 37-44.	0.6	6
25	The patient with heart failure in the face of the coronavirus disease 2019 pandemic: an expert opinion of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2020, 78, 618-631.	0.6	4
26	Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle. Cardiology Journal, 2020, 27, 726-734.	1.2	4
27	First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases. Cardiology Journal, 2020, 27, 639-641.	1.2	Ο
28	From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and a challenging diagnosis. Polish Archives of Internal Medicine, 2020, 130, 153-154.	0.4	0
29	Cardiac implantable electronic devices with a defibrillator component and allâ€cause mortality in left ventricular assist device carriers: results from the PCHFâ€VAD registry. European Journal of Heart Failure, 2019, 21, 1129-1141.	7.1	27
30	99mTc-HMPAO-labeled leukocyte SPECT/CT and transthoracic echocardiography diagnostic value in infective endocarditis. International Journal of Cardiovascular Imaging, 2019, 35, 749-758.	1.5	32
31	Arterial stiffness in adult patients after coarctation of aorta repair and with bicuspid aortic valve. Acta Cardiologica, 2019, 74, 517-524.	0.9	6
32	Clinical classification of rare cardiac arrhythmogenic and conduction disorders, and rare arrhythmias. Polish Archives of Internal Medicine, 2019, 129, 154-159.	0.4	4
33	Relationships between left ventricular geometry and remodeling in dilated cardiomyopathy. Minerva Cardioangiologica, 2019, 67, 261-271.	1.2	0
34	Twelve-month kinetics of circulating fibrosis-linked microRNAs (miR-21, miR-29, miR-30, and miR-133a) and the relationship with extracellular matrix fibrosis in dilated cardiomyopathy. Archives of Medical Science, 2019, 18, 480-488.	0.9	1
35	The relationship between myocardial fibrosis and myocardial micro <scp>RNA</scp> s in dilated cardiomyopathy: A link between mirâ€133a and cardiovascular events. Journal of Cellular and Molecular Medicine, 2018, 22, 2514-2517.	3.6	20
36	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94

PaweÅ, RubiÅ›

#	Article	lF	CITATIONS
37	Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. Advances in Medical Sciences, 2018, 63, 160-166.	2.1	15
38	Temporal changes in the pattern of invasive angiography use and its outcome in suspected coronary artery disease: implications for patient management and healthcare resource utilization. Postepy W Kardiologii Interwencyjnej, 2018, 14, 247-257.	0.2	3
39	Right ventricular morphology and function is not related with microRNAs and fibrosis markers in dilated cardiomyopathy. Cardiology Journal, 2018, 25, 722-731.	1.2	3
40	Safety profile of end-stage heart failure patients implanted with left ventricular assist devices. Krakow two-year observational all-comers study on left ventricular assist device recipients. Kardiologia Polska, 2018, 76, 1369-1371.	0.6	0
41	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. Cardiologia Croatica, 2018, 13, 358-360.	0.0	Ο
42	12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. Cytokine, 2017, 96, 217-227.	3.2	9
43	Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR. Heart and Vessels, 2017, 32, 714-725.	1.2	6
44	Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy. International Journal of Cardiology, 2017, 231, 201-206.	1.7	36
45	Comparison of two European models estimating risk of Âsudden cardiac death in hypertrophic cardiomyopathy. Acta Cardiologica, 2017, 72, 446-452.	0.9	Ο
46	Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy. Polish Archives of Internal Medicine, 2017, 127, 216-218.	0.4	2
47	Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy. Inflammation Research, 2016, 65, 941-949.	4.0	20
48	The paramount importance of repeated left ventricular endomyocardial biopsy during the diagnosis of restrictive cardiomyopathy due to AL cardiac amyloidosis. Kardiologia Polska, 2016, 74, 796-796.	0.6	5
49	Aspirin resistance in adult patients after Fontan surgery. International Journal of Cardiology, 2015, 181, 19-26.	1.7	21
50	Complete recovery of a patient with cardiogenic shock due to parvovirus B19 fulminant myocarditis after treatment with extracorporeal membrane oxygenation and intravenous immunoglobulin. Polish Archives of Internal Medicine, 2015, 125, 199-201.	0.4	0
51	Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study. Acta Cardiologica, 2011, 66, 159-165.	0.9	30
52	The prognostic role of exercise echocardiography in heart failure. Kardiologia Polska, 2011, 69, 656-63.	0.6	5
53	Myocardial Viability Detected by Myocardial Contrast Echocardiography—Prognostic Value in Patients after Myocardial Infarction. Echocardiography, 2010, 27, 430-434.	0.9	7
54	The dynamic assessment of rightâ€ventricular function and its relation to exercise capacity in heart failure. European Journal of Heart Failure, 2010, 12, 260-267.	7.1	17

PaweÅ, RubiÅ›

#	Article	IF	CITATIONS
55	Usefulness of the Evaluation of Isovolumic and Ejection Phase Myocardial Signals during Stress Echocardiography in Predicting Exercise Capacity in Heart Failure Patients. Echocardiography, 2009, 26, 1050-1059.	0.9	6
56	Atherosclerosis progression affects the relationship between endothelial function and aortic stiffness. Atherosclerosis, 2009, 204, 250-254.	0.8	23
57	Supra-aortic extracranial artery atherosclerotic lesions in patients diagnosed for coronary artery disease: prevalence and predictors. Kardiologia Polska, 2009, 67, 985-91.	0.6	7
58	Assessment of resting perfusion defect in patients with acute myocardial infarction: comparison of myocardial contrast echocardiography with contrast-enhanced magnetic resonance imaging. Kardiologia Polska, 2009, 67, 1013-8.	0.6	1
59	Usefulness of the Evaluation of Left Ventricular Diastolic Function Changes During Stress Echocardiography in Predicting Exercise Capacity in Patients with Ischemic Heart Failure. Journal of the American Society of Echocardiography, 2008, 21, 834-840.	2.8	49
60	Renal artery stenosis in patients with coronary artery disease. Kardiologia Polska, 2008, 66, 856-62; discussion 863-4.	0.6	17
61	Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. Nephrology Dialysis Transplantation, 2007, 23, 580-585.	0.7	27
62	Aortic Pulse Wave Velocity and Carotid-Femoral Pulse Wave Velocity: Similarities and Discrepancies. Hypertension Research, 2007, 30, 1151-1158.	2.7	30
63	Anti-phospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction. Medical Science Monitor, 2003, 9, BR105-9.	1.1	4